There will be catalysts before and after the mid July AD Conference in Copenhagen, but Copenhagen is the centerpiece. It is where Gerald introduces LymPro to the world and releases data! From Copenhagen there will be a countdown to LymPro commercialization, which will probably be less than 90 days. LymPro's commercial launch and AMBS' launch to the NASDAQ are interrelated and will happen around the same time. (Octoberish?) To the extent he can I wouldn't be surprised if Gerald is choreographing the timing of each catalyst in order to reach the highest pps pinnacle prior to up listing. Catalysts released before and after Copenhagen will include: Wolfram's data, Retinitis functionality data, MANF/Wolframs and MANF/Retinitis and Eltoprazine orphan status, possible partnerships for MANF indications as well as Eltoprazine, GDNF results on their Phase 2 trial (effecting MANF PD), MANF toxicaology report, LymPro Revenue Guidance, LymPro Commercialization, the beginning of Eltoprazine clinical phase 2b/3 trial, LymPro/Concussion testing results, announcement of up listing, positions taken by JP Morgan, Fidelity, and BofA, etc, and maybe even the Goose that lays the golden egg........announcements of Phenoguard discoveries!! Gerald is going to synchronize these catalysts and Lincoln Park is going to help him CAPITALIZE!! Hang on to your shares until way after the New Year!!
Don't count out going for an orphan status for Type 1 Diabetes. Something like new onset type 1 diabetes to preserve pancreatic beta cell function. If the data is good they will exhaust all opportunities and in my opinion going after orphan status for type 1 diabetes is one of them.
I think this whole "orphan status" thing is being over-thinked a bit. Sure, they may be looking at every conceivable angle, but as it's related to Diabetes, one need look no further than Wolframs. The whole idea (obviously) is to get MANF to market as quickly as possible. Wolframs or R.P. is all you need. After that, the larger indications.
Another thought. GC has even discussed orphan designation for Eltoprizine. I don't believe that's realistic. I think he said that to get just a little more buzz, as "orphan" is the hot topic.
Oh, and I forgot, Gerald will undoubtedly be appearing on CNN, GMA, 60 Minutes, etc, as he initiates his media blitz over the historic launching of LymPro! I would hope he does that right as it is ready to commercialize so he can tell people the test is ready immediately!! This media blitz will really put AMBS on the map and bring scores of new investors to the stock. In pre-reverse split numbers, I don't see how we're not at least to .40 cents by year end at the worst, and over $1.00 on the upside.
Let's hope it's not CNN, check there ratings, no one watches CNN, now if he goes on the #1 rated news channel(fox news) , then millions of people will hear about it. Just go check the ratings, you'll understand why CNN is the joke of late night talk show host about there minuscule ratings.
I also believe that there will be a media blitz, and I think it will be HOT. However, CG will not make a single move, aside from investor conferences and such, until LymPro has cleared regulatory hurdles, and is officially on the market.
Oh, and I forgot another thing: there are probably several things Gerald has brewing that we don't even know about. For example: Docstock predicted that we would acquire another company. What's that all about? That's what I'm talking about. The catalysts I've mentioned above are just the ones we know about. Trust me, there's a lot more cooking than we know about and they are going to throw the everything including the kitchen sink to get us as high as possible for the up listing!! Lincoln Park is going to see to it they score big time!